Key Metrics
CiteScore 

5.9
Eigenfactor 

0.001 - 0.005
H-Index 

57
Impact Factor 

< 5
SJR 

Q2Pharmacology (medical)

SNIP 

1.15
Recommended pre-submission checks
Powered by 

Topics Covered on American Journal of Cardiovascular Drugs
American Journal of Cardiovascular Drugs Journal Specifications
| Overview | |
| Publisher | ADIS INT LTD |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2001 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in American Journal of Cardiovascular Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in American Journal of Cardiovascular Drugs
Iron Deficiency as a Modifiable Risk Factor in Heart Failure: Evidence and Recommendations.
- 28 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions
Midodrine to Facilitate Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Promising Breakthrough or Just a False Hope?
- 15 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions
Comment on: "A Retrospective Cohort Study on Long‑Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion".
- 6 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions
Early SGLT2i Therapy Facilitates In-Hospital ARNI Introduction Improving 6-Month Systolic Function in Patients with HFrEF.
- 6 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions
Authors' Reply to Pang et al: "A Retrospective Cohort Study on Long-Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion".
- 6 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions
Effect of Tirzepatide on Cardiovascular Outcomes.
- 1 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions
Iron Deficiency as a Modifiable Risk Factor in Heart Failure: Evidence and Recommendations.
- 28 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions
Midodrine to Facilitate Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Promising Breakthrough or Just a False Hope?
- 15 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions
Comment on: "A Retrospective Cohort Study on Long‑Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion".
- 6 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions
Early SGLT2i Therapy Facilitates In-Hospital ARNI Introduction Improving 6-Month Systolic Function in Patients with HFrEF.
- 6 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions
Authors' Reply to Pang et al: "A Retrospective Cohort Study on Long-Term Outcomes of Ticagrelor Versus Clopidogrel After Retrograde Percutaneous Coronary Intervention for Chronic Total Occlusion".
- 6 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions
Effect of Tirzepatide on Cardiovascular Outcomes.
- 1 Oct 2025
- American journal of cardiovascular drugs : drugs, devices, and other interventions